BACKGROUND: Combination metronomic topotecan plus pazopanib is active against preclinical models of gynecological cancer. Both agents are substrates for ATP-binding cassette family transporters so there is an increased likelihood for pharmacokinetic (PK) drug-drug interactions. PATIENTS AND METHODS: PK analyses of topotecan were performed during three cycles of a phase I dose-escalation study of metronomic topotecan and pazopanib in consenting adult patients with gynecological cancer. Concentration time data were analyzed using a population PK approach. RESULTS: Twenty-one patients were evaluable for serial PK studies. Considerable inter- and intra-patient variability was observed in the PK parameters, attributable primarily to highly variable oral bioavailability. No difference in topotecan disposition was detected between administration cycles, nor between the off- versus on-pazopanib studies. CONCLUSION: The lack of a statistically significant drug-drug interaction agrees with preclinical findings suggesting that pazopanib does not influence the PK of metronomic topotecan. No adjustment of low dose metronomic topotecan dosing is merited when used in conjunction with pazopanib.
BACKGROUND: Combination metronomic topotecan plus pazopanib is active against preclinical models of gynecological cancer. Both agents are substrates for ATP-binding cassette family transporters so there is an increased likelihood for pharmacokinetic (PK) drug-drug interactions. PATIENTS AND METHODS: PK analyses of topotecan were performed during three cycles of a phase I dose-escalation study of metronomic topotecan and pazopanib in consenting adult patients with gynecological cancer. Concentration time data were analyzed using a population PK approach. RESULTS: Twenty-one patients were evaluable for serial PK studies. Considerable inter- and intra-patient variability was observed in the PK parameters, attributable primarily to highly variable oral bioavailability. No difference in topotecan disposition was detected between administration cycles, nor between the off- versus on-pazopanib studies. CONCLUSION: The lack of a statistically significant drug-drug interaction agrees with preclinical findings suggesting that pazopanib does not influence the PK of metronomic topotecan. No adjustment of low dose metronomic topotecan dosing is merited when used in conjunction with pazopanib.
Entities:
Keywords:
Metronomic topotecan; drug drug interaction; gynecological cancer; pazopanib; pharmacokinetics
Authors: S Z Soffer; J T Moore; E Kim; J Huang; A Yokoi; C Manley; K O'Toole; C Stolar; W Middlesworth; D J Yamashiro; J J Kandel Journal: J Pediatr Surg Date: 2001-08 Impact factor: 2.545
Authors: S Z Soffer; E Kim; J T Moore; J Huang; A Yokoi; C Manley; K O'Toole; W Middlesworth; C Stolar; D Yamashiro; J Kandel Journal: J Pediatr Surg Date: 2001-12 Impact factor: 2.545
Authors: J W Jonker; J W Smit; R F Brinkhuis; M Maliepaard; J H Beijnen; J H Schellens; A H Schinkel Journal: J Natl Cancer Inst Date: 2000-10-18 Impact factor: 13.506
Authors: J G Wall; H A Burris; D D Von Hoff; G Rodriguez; R Kneuper-Hall; D Shaffer; T O'Rourke; T Brown; G Weiss; G Clark Journal: Anticancer Drugs Date: 1992-08 Impact factor: 2.248
Authors: C M F Kruijtzer; J H Beijnen; H Rosing; W W ten Bokkel Huinink; M Schot; R C Jewell; E M Paul; J H M Schellens Journal: J Clin Oncol Date: 2002-07-01 Impact factor: 44.544
Authors: F Léger; W J Loos; J Fourcade; R Bugat; M Goffinet; R H J Mathijssen; J Verweij; A Sparreboom; E Chatelut Journal: Br J Cancer Date: 2004-01-26 Impact factor: 7.640
Authors: Rebecca A Previs; Guillermo N Armaiz-Pena; Yvonne G Lin; Ashley N Davis; Sunila Pradeep; Heather J Dalton; Jean M Hansen; William M Merritt; Alpa M Nick; Robert R Langley; Robert L Coleman; Anil K Sood Journal: Mol Cancer Ther Date: 2015-10-29 Impact factor: 6.261
Authors: Arif Manji; Yvan Samson; Rebecca J Deyell; Donna L Johnston; Victor A Lewis; Alexandra P Zorzi; Jason N Berman; Kathy Brodeur-Robb; Ellen Morrison; Lynn Kee; Sushil Kumar; Sylvain Baruchel; James A Whitlock; Daniel A Morgenstern Journal: Cancers (Basel) Date: 2022-06-17 Impact factor: 6.575
Authors: B Milojkovic Kerklaan; M P J Lolkema; L A Devriese; E E Voest; A Nol-Boekel; M Mergui-Roelvink; M Langenberg; K Mykulowycz; J Stoebenau; S Lane; P Legenne; P Wissel; D A Smith; B J Giantonio; J H M Schellens; P O Witteveen Journal: Br J Cancer Date: 2015-08-20 Impact factor: 7.640